Last reviewed · How we verify
AST-001
AST-001 is a small molecule that targets the SGLT2 receptor.
AST-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AST-001 |
|---|---|
| Sponsor | Ascentawits Pharmaceuticals, Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, AST-001 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children (PHASE3)
- A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |